In Vivo is part of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Mike Ward

London, UK
Mike has been writing, analysing and commenting on the life sciences industry for more than 30 years as a journalist and investment bank analyst. He has focused on business models, R&D strategies and how to finance innovation, and is often called upon by the industry's key stakeholders to provide thought leadership. In 2010 he was named European Mediscience Commentator of the Year and has appeared on the shortlist for that award on numerous occasions. When not commentating on all things pharma, Mike is engaged actively in pub quizzes, either as a competitor or a compiler. He is also a qualified FA soccer coach.
Advertisement
Set Alert for Articles By Mike Ward

Latest From Mike Ward

Atlantic Phase III Setback Might Prompt Pouchitis Endpoint Rethink

Despite failing to meet the co-primary endpoints in a Phase III trial, Atlantic Healthcare believes alicaforsen enema could still be approved in orphan-designated pouchitis.

Gastrointestinal Inflammation

Wellington Partners Maintains Medtech Interests With New €210M Eurocentric Fund WPLS-V

While other venture capitalists are curbing their efforts in medtech, Wellington Partners intends to maintain its support for the sector earmarking about half of its new €210m WPLS-V fund for European medtech opportunities.

Medical Device Financing

Wellington Partners Unveils €210m Eurocentric Biotech/Medtech Fund WPLS-V

With its WPLS-IV fund now fully committed, Wellington Partners has returned to the market and raised €210m in its WPLS-V fund which will focus on European biotech and medtech opportunities.

Financing StartUps and SMEs

Medicxi Closes €400m Medicxi III Biotech Fund In 6 Weeks

European life sciences investment firm Medicxi shows institutional investor appetite for life sciences venture capital is still strong as it secures €400m in an over-subscribed offering.

Commercial Financing

Genentech Signs Up Sosei Heptares GPCR Smarts For $1bn+ Deal

The companies have agreed to a multi-year, multi-target research collaboration and license deal to discover and develop medicines that modulate GPCR targets across a range of diseases.

Deals Commercial

AM-Pharma Raises €116m To Finance Solo Phase III Trial

Following Pfizer’s decision not to take up an option to acquire the Dutch company, AM-Pharma has returned to the venture capital market to get backing for a single pivotal Phase III trial of reCAP in acute kidney injury.

Financing Clinical Trials
See All
Advertisement
UsernamePublicRestriction

Register